Waldenström macroglobulinemia

WM is an IgM-associated lymphoplasmacytic lymphoma. Bone marrow morphology, flow cytometry, serum protein studies and clinical findings distinguish it from IgM MGUS, other B-cell lymphomas and rare IgM myeloma. Classification frameworks differ around low-level marrow involvement; a single percentage or IgM value should not replace integrated pathology.

MYD88 and CXCR4 testing can influence the expected response and speed of response to BTK inhibition. MYD88 mutation supports the diagnostic picture but is neither unique to WM nor mandatory in every case. A negative result needs interpretation with assay sensitivity and alternative diagnoses.

Observation is an active plan for people without treatment-triggering symptoms or threatened organ function. Follow-up tracks blood counts, IgM, examination and symptoms rather than aiming to normalize every abnormal laboratory result.

Reasons to start therapy include disease-related anemia or thrombocytopenia, troublesome lymph nodes or spleen enlargement, constitutional symptoms, hyperviscosity and clinically important IgM-related nerve, kidney or other organ damage. Very high or rapidly changing IgM warrants assessment of imminent complications even before typical symptoms develop.

Visual disturbance, headache, confusion, mucosal bleeding or breathlessness may reflect hyperviscosity. Symptomatic hyperviscosity requires urgent care; plasma exchange can rapidly lower circulating IgM while disease-directed treatment takes effect. Exchange treats the protein problem temporarily, not the marrow lymphoma itself.

Rituximab can cause a temporary IgM rise, called flare, which is different from true progression. When IgM or viscosity creates risk, clinicians may alter the order of treatment or use plasma exchange. Patients should not interpret the first higher IgM result in isolation or delay care for new symptoms.

Bendamustine–rituximab and dexamethasone–cyclophosphamide–rituximab are established fixed-duration approaches. A covalent BTK inhibitor is an alternative that usually continues until progression or unacceptable toxicity. Selection weighs marrow reserve, infections, neuropathy, cardiac history, bleeding, drug interactions and the preference for time off treatment.

Zanubrutinib has a US adult WM indication. ASPEN found effective disease control with both zanubrutinib and ibrutinib and fewer selected cardiovascular adverse events with zanubrutinib, but more neutropenia. The original primary response comparison did not reach statistical significance; the study should not be presented as proof that one drug improves survival for everyone.

At relapse, distinguish intolerance from resistance and biochemical change from clinically significant progression. A prior regimen may sometimes be reused after a durable response; otherwise a different drug class or a trial may be appropriate. Abrupt interruption of BTK inhibition can produce IgM rebound, so surgery, toxicity pauses and switching need an agreed plan.

A 2026 retrospective comparison of venetoclax and pirtobrutinib provides sequencing and molecular-risk information, including rebound during some transitions. It is not a randomized ranking or proof of a WM approval for either drug. Access and off-label use need explicit local review.

Numbness or imbalance may arise from IgM-associated neuropathy, treatment toxicity or another condition. Kidney or cardiac abnormalities may warrant evaluation for monoclonal protein injury or AL amyloidosis. Treating these complications requires identifying their cause, not simply choosing the fastest IgM-lowering drug.

Bing–Neel syndrome means central nervous system infiltration and needs neurological, MRI and cerebrospinal-fluid assessment. The IWWM-12 consensus recognizes zanubrutinib as a standard treatment option and updates response interpretation; persistent CSF findings are interpreted with clinical and imaging response.

Rapidly enlarging nodes, a marked LDH rise or new aggressive symptoms may require biopsy for transformation to large B-cell lymphoma. Transformed disease follows an aggressive-lymphoma pathway rather than simply escalating ordinary WM therapy.

Fixed-duration oral combinations are attractive research questions, but efficacy cannot be separated from safety. The final report of an ibrutinib–venetoclax phase II study describes early termination of treatment and enrollment because of ventricular arrhythmias, including fatal events. This combination should not be promoted as a routine convenient substitute.

Follow-up assesses symptoms, blood counts, IgM trends and treatment-specific risks. Review infection prevention, vaccines, blood pressure, bruising and interactions with anticoagulants or other medicines. Good laboratory response and restored daily function are related but not identical outcomes.

Bring marrow pathology and flow cytometry, MYD88/CXCR4 results with test method, IgM and blood-count trends, viscosity and eye findings if relevant, previous drugs and reasons for stopping, and cardiac or neuropathy assessments. Ask whether the immediate aim is preventing organ harm, controlling lymphoma, or both, and whether the proposed regimen is fixed-duration or continuous.